Observational study on the effectiveness of Osimertinib for lung cancer patients
Efficacy of Osimertinib in Patients With Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
This study looks at how well the lung cancer drug Osimertinib works for people with advanced non-small cell lung cancer by tracking their usual treatment and health over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hunan Province Tumor Hospital Academic / other |
| Locations | 1 site (Changsha, Hunan) |
| Trial ID | NCT06174857 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect epidemiological data on the efficacy of Osimertinib in patients diagnosed with advanced non-small cell lung cancer. Participants will not receive any experimental treatment; instead, their existing medical practices will be monitored to assess the drug's effectiveness in a real-world setting. The study will include patients who meet specific criteria, such as having measurable lesions as defined by RECIST 1.1. Data will be gathered prospectively to ensure accurate and relevant findings.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology.
Not a fit: Patients who do not have measurable lesions or those with other types of lung cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the real-world effectiveness of Osimertinib for patients with advanced lung cancer.
How similar studies have performed: While this study is observational and does not involve new interventions, previous studies on Osimertinib have shown promising results in treating lung cancer, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must be ≥18 years. * Provision of fully informed consent prior to any study specific procedures. * Advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology. * According to the RECIST 1.1 standard, the patient must have at least one measurable lesion. Exclusion Criteria: * None
Where this trial is running
Changsha, Hunan
- Hunan Cancer hospital — Changsha, Hunan, China (Recruiting)
Study contacts
- Principal investigator: Yongchang Zhang, MD — Hunan Cancer Hospital
- Study coordinator: Yongchang C Zhang, MD
- Email: zhangyongchang@csu.edu.cn
- Phone: +8613873123436
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.